They came off the antidepressant. The side effects didn’t lift.
- Sex, feeling, memory, sleep — numbed by an antidepressant.
- Not just SSRIs — SNRIs too. Thousands affected.
- No dedicated ICD code. No treatment. Recognition is partial.
The EMA accepted in 2019 that sexual dysfunction can persist after serotonergic antidepressants are stopped.EMA PRAC, 2019
Thirty-two years passed between the first reports and formal regulatory recognition.Regulatory record
More than 60 million prescriptions a year, and almost no doctor is taught this exists.Prescribing data
No dedicated ICD code — cases fall into a generic bucket, so PSSD is never counted as itself.ICD-10 F52.8
What is PSSD?
Post-SSRI Sexual Dysfunction (PSSD) is a condition in which sexual, neurological, and emotional side effects persist indefinitely after discontinuing SSRI or SNRI antidepressants. Patients report genital numbness, loss of libido, emotional blunting, and anhedonia that do not resolve weeks, months, or even years after stopping the medication.
SSRIs work by blocking the reuptake of serotonin, flooding synapses with excess serotonin. Research suggests that prolonged serotonin receptor down-regulation and epigenetic changes to gene expression may underpin the persistence of symptoms. The exact mechanism remains unclear, and to date no pharmaceutical company has publicly funded research into the condition.
The European Medicines Agency (EMA) formally recognised PSSD in 2019, requiring updated product labels for SSRIs and SNRIs across Europe. Despite this milestone, most prescribing physicians remain unaware of the condition, and no diagnostic test or approved treatment exists.
Persistent symptoms reported by patients
PSSD affects sexual function, neurological health, and physical wellbeing. Symptoms may appear during SSRI use and persist after stopping, or emerge upon discontinuation.
Sexual
5- Genital numbness / reduced sensation
- Complete loss of libido
- Erectile dysfunction
- Pleasureless or muted orgasms
- Vaginal dryness
Neurological
5- Emotional blunting
- Anhedonia (inability to feel pleasure)
- Depersonalisation / derealisation
- Cognitive fog and memory issues
- Insomnia and sleep disruption
Physical
3- Chronic fatigue
- Reduced tactile sensation
- Muscle weakness
This list is not exhaustive — it reflects the symptoms most commonly reported by patients, not every symptom that has been described.
PSSD by the numbers
A history of delayed recognition
Prozac approved by FDA
Clinical trials report sexual dysfunction in 2-16% of participants. Manufacturer later accused of under-reporting.
GSK $3 billion settlement
GlaxoSmithKline pays the largest healthcare fraud settlement in US history, partly related to Study 329 and the promotion of Paxil (paroxetine) to children.
EMA recognises PSSD
The European Medicines Agency formally acknowledges that SSRI/SNRI sexual dysfunction can persist after discontinuation. Product labels updated across Europe.
MedDRA term created — but buried
MedDRA adds “Post-SSRI sexual dysfunction” (code 10086208) and a standardised query for sexual dysfunction. But the term is a lowest-level term sitting under the preferred term “Sexual dysfunction” — so reports are absorbed into a generic category, and regulators’ published data still does not count PSSD separately.
Public Citizen petition dismissed
A petition to the FDA by Public Citizen requesting stronger warnings is dismissed, leaving US patients without adequate regulatory protection.
Published science on PSSD
All PSSD research to date has been patient-funded or conducted by independent academics. No pharmaceutical company has publicly contributed to PSSD research.
Healy et al.
Characterization of PSSD as a distinct clinical entity with persistent sexual dysfunction, emotional blunting, and cognitive impairment following SSRI use.
Giatti et al. (2025)
Demonstrated that paroxetine causes persistent changes to dopamine pathways in animal models, providing a potential neurobiological mechanism for PSSD.
Csoka & Szyf (2009)
Proposed that SSRIs induce epigenetic changes (DNA methylation and histone modifications) that persist after drug withdrawal, underpinning the chronicity of PSSD.
Rice et al. (2025)
Qualitative study documenting patient experiences with PSSD, highlighting the psychosocial impact and the difficulty many patients describe in having their symptoms recognised.
The drugs involved
PSSD has been reported with SSRIs, SNRIs and other serotonergic antidepressants — not one drug, a whole class. Risk varies, with paroxetine consistently showing the highest incidence of persistent sexual side effects.
Paroxetine
Paxil / Seroxat — SSRISubject of the largest healthcare fraud settlement in US history ($3B, GSK, 2012). Study 329 showed it was ineffective in adolescents while GSK promoted it for children. Most frequently cited in PSSD case reports.
Sertraline
Zoloft — SSRIOne of the most widely prescribed SSRIs globally. Frequently reported in PSSD cases, particularly for persistent genital numbness and emotional blunting.
Fluoxetine
Prozac — SSRIThe first SSRI approved by the FDA (1987). Clinical trials reported sexual dysfunction in 2-16% of participants. The manufacturer was subsequently accused of under-reporting true incidence.
Escitalopram
Lexapro / Cipralex — SSRIA newer SSRI often marketed as having fewer side effects. PSSD cases continue to be reported, particularly involving loss of libido and anorgasmia.
Citalopram
Celexa — SSRIThe racemic parent compound of escitalopram. Associated with persistent sexual dysfunction and emotional numbing in post-marketing reports.
Venlafaxine
Effexor — SNRIKnown for severe withdrawal effects and persistent sexual dysfunction after discontinuation.
Duloxetine
Cymbalta — SNRIPrescribed for depression, anxiety, and chronic pain. Reports of persistent sexual and emotional side effects after stopping continue to accumulate.
Desvenlafaxine
Pristiq — SNRIVenlafaxine's active metabolite, marketed separately. Carries the same class-wide reports of persistent sexual dysfunction after discontinuation.
Vortioxetine
Trintellix / Brintellix — other serotonergicA newer multimodal antidepressant, not an SSRI or SNRI, but still acting on serotonin. PSSD-pattern cases are reported against it too.
Paroxetine mesylate
Brisdelle — SSRI, non-psychiatric useThe same molecule as above, sold at a lower dose for menopausal hot flushes — a reminder that exposure isn't limited to a psychiatric prescription.
This list is not exhaustive. Many more drugs have been linked to PSSD-pattern symptoms. The drugs above are simply the ones reported most often. Any medicine acting on serotonin may carry the same risk — including some prescribed for reasons that have nothing to do with mental health.
The gap between reality and the data
PSSD is one of the most underreported adverse drug reactions in modern medicine. The numbers reveal a system that systematically obscures the true scale of harm.
No dedicated ICD code
PSSD has no International Classification of Diseases (ICD) code of its own — Orphanet maps it only to F52.8, a residual “other sexual dysfunction” bucket, so there is nothing to diagnose it as. Without a code, the condition is invisible to health systems, insurance databases, and epidemiological research. Patients are coded under generic categories like "sexual dysfunction NOS," erasing PSSD from the medical record entirely.
Patients do not make the connection
Many patients are never told that SSRIs can cause persistent sexual dysfunction. When symptoms continue after stopping the drug, they blame ageing, stress, or their underlying depression — not the medication. Doctors frequently reinforce this misattribution.
Doctors dismiss reports
Patients who do recognise the connection often face clinical dismissal. Studies show that physicians frequently attribute PSSD symptoms to the original psychiatric condition rather than the drug itself, discouraging formal adverse event reporting.
Under-reporting shapes the evidence itself
A drug’s safety profile is assembled from what gets reported. So under-reporting does not only hide individual cases — it shapes what the evidence appears to show to regulators and prescribers, and a condition that is rarely reported looks rarer than it is. That is the argument for reporting, whatever else you conclude.
How to get help
You do not have to face this alone. Here is where to start.
WhatsApp support groups
Connect with other PSSD patients in private, moderated groups. Share experiences and coping strategies with people who understand.
Join the patient registry
Add your case to the SIDEfxHUB registry. Your anonymised data helps researchers understand PSSD and work toward treatment.
Report your side effects
Filing a report with your national regulator (FDA, MHRA, EMA) is critical. Low reporting rates make these drugs appear safer than they are.
Support library
Research papers, patient stories, media coverage, and practical resources — all in one place.
Sources & databases
All data on this page is sourced from peer-reviewed research and official regulatory databases.
PubMed — PSSD Research
Search peer-reviewed publications on Post-SSRI Sexual Dysfunction.
Search PubMed →EMA — PSSD Recognition
The 2019 EMA decision formally recognising PSSD.
View decision →FDA FAERS
The FDA Adverse Event Reporting System — the primary US database for drug safety reports.
Visit database →PSSD Network
Patient advocacy and research funding for PSSD.
Visit website →RxISK — PSSD
Independent drug safety research and PSSD resources.
Visit website →WHO VigiBase
Global database of safety reports from 153 countries.
Visit database →I think I have PSSD. What now?
If you recognise these symptoms, here are 5 steps you can take right now.
You are not imagining this
PSSD is recognised by the EMA and documented in peer-reviewed literature. Your symptoms are real, documented, and shared by thousands worldwide.
Connect with others
Join a WhatsApp peer support group — talk to people who understand exactly what you're going through.
Report your side effects
Report to your country's health regulator. Every report makes these conditions harder to ignore.
Read about managing symptoms
Visit our Support Library for guides on coping strategies, talking to your doctor, and lifestyle approaches.
Join the registry
Register your experience anonymously. Your data supports research and helps prove the true scale of these conditions.
Help build the evidence base
Every registrant is a data point researchers and regulators can act on — it's what got PSSD its EMA recognition in 2019, and what moves the next step. Takes about three minutes, and you can stay anonymous.